Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies

Razan Mohty1,6, Rémy Dulery2,3,6, Abdul Hamid Bazarbachi1,5, Malvi Savani5, Rama Al Hamed4, Ali Bazarbachi1 and Mohamad Mohty2,3

© The Author(s) 2021

INTRODUCTION
Decade after decade, the prognosis of classical Hodgkin lymphoma (cHL) has improved with the advancement of novel treatment strategies [1] resulting in high cure rates. In early stage disease, using the European Organization for Research and Treatment of Cancer staging criteria, estimates of 5-year overall survival (OS) range from 99.4 to 96.0%, for favourable and unfavourable risk, respectively, a small but significant difference (p < 0.001) [2]. In the advanced-stage disease, 5-year OS ranges from 56 to 89% [3]. However, key unmet clinical needs remain. New treatment strategies are necessary to prevent or cure relapsed/refractory (R/R) disease, reduce treatment-related morbidity, ameliorate quality of life (QoL), and improve outcomes of patients older than 60 years. This review aims to summarize the most important advances in cHL management to address these needs in both frontline and relapse settings.

FRONTLINE THERAPY IN HODGKIN LYMPHOMA
Risk-adapted and response-adapted frontline strategies
Most patients with cHL will be cured with standard treatment. However, they are at risk of potential long-term complications including the exponential increase in cardiopulmonary toxicities and secondary malignancies as well as QoL impairment [4]. Consequently, the latest advances in the management of cHL have focused on optimizing treatment strategies to improve outcome while reducing toxicity. Identifying patients at low or high risk of recurrence is critical to avoid over- or under-treatment. The fluorodeoxyglucose positive emission tomography (PET) scan has become an essential tool for staging and therapeutic guidance [5–7]. The predictive power of PET can also be improved by assessing the metabolic tumour volume (MTV) measured by drawing the volume of fluorodeoxyglucose-avid disease in three dimensions [8, 9].

The standard of care for early stage cHL is doxorubicin (or adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) and form the backbone of frontline management in North America regardless of the stage. The benefit of adding radiation therapy was tested in the early favourable setting by the HD10 trial showing that the addition of 20 Gy of involved-field radiotherapy (IFRT) to 2 cycles of ABVD is as effective as 30 Gy [10]. In the RAPID trial, patients who had a negative PET after 3 cycles of ABVD had a very good prognosis whether consolidation radiation therapy was given or not with an absolute difference in the 3-year progression free survival (PFS) of -3.8% (95% confidence interval (CI), −8.8 to 1.3) [11]. The H10 EORTC/Lysa trial demonstrated the benefit of a PET-adapted strategy after 2 cycles of ABVD in favourable and unfavourable early stage cHL. Patients either received 1 additional cycle of ABVD with involved-node radiation therapy (INRT) regardless of PET results (standard arm) or stratified to receive additional ABVD in PET negative patients or escalated (e)BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine (or oncovin), procarbazine, prednisolone) with INRT in PET positive patients. Switching to eBEACOPP with INRT significantly improved 5-year PFS from 77.4% in the standard arm to 90.6% in the intensification arm (Hazard ratio [HR] = 0.42; 95%CI, 0.23–0.74; P = .002). The omission of INRT lead to inferior outcome in PET negative patients compared to the standard arm especially in favourable risk patients who received a total of four ABVD cycles (HR, 1.45; 95% CI, 0.8–2.5). Long-term follow-up from the German Hodgkin Study Group (GHSG) HD14 randomized trial including young patients showed improved disease control with two cycles...
of eBEACOPP, followed by two cycles of ABVD (2 + 2) compared with four cycles of ABVD alone (4xABVD). Patients receiving 2 + 2 had higher 10-year PFS of 91.2% compared to 85.6% with 4xABVD (HR = 0.052, 95%CI 0.386–0.704, p < 0.0001). However, this did not translate into an OS difference. Therefore, 2 + 2 is the GHSG standard of care for patients aged ≤60 years with early unfavourable cHL. Yet, this approach is not widely used. Higher toxicities associated with the eBEACOPP regimen including short- and long-term toxicities namely haematologic malignancies makes it less convenient. (Table 1) [12, 13].

In the HD17 phase 3 trial, 11,100 patients were randomized to receive either 2 + 2 followed by 30 Gy IFRT or PET4-guided treatment using 2 + 2 regimen followed by 30 Gy IFRT only in patients with positive end of treatment PET. Five-year PFS was 97.3% in the standard arm and 95.1% in the PET4-guided treatment group (HR = 0.523, 95%CI 0.226–1.211). This study shows for the first time that consolidation radiotherapy can safely be omitted without significant loss of efficacy in newly diagnosed early stage unfavourable cHL in PET4 negative patients receiving 2 + 2 chemotherapy, thus reducing the proportion of patients at risk of late toxic effects of radiotherapy [14].

In advanced-stage cHL, the HD18 trial demonstrated the non-inferiority of reducing therapy to a total of four cycles of eBEACOPP instead of six or eight cycles in the case of PET2 negativity after two cycles of eBEACOPP (5-year PFS 92.2% vs 90.8%, respectively, 95% CI 2.7–5.1) [15]. Also, the AHL2011 Lysa trial validated an alternative PET-adapted approach after two cycles of eBEACOPP in patients with advanced cHL. Patients with PET2-negative disease received four additional cycles of ABVD and patients with PET2-positive disease received four additional cycles of eBEACOPP leading to similar 4-year PFS 87.1% vs 87.4%, respectively (p = 0.68) and decrease toxicity in the PET2-negative arm, mainly cytopenia and sepsis [16, 17]. Another PET-directed therapeutic strategy was studied in the RATHL trial, which included 1214 patients with newly diagnosed advanced cHL [18]. After two cycles of ABVD, PET negative patients were randomized to receive either four cycles of AVD, omitting bleomycin, or ABVD. Progressing patients received eBEACOPP. Three-years PFS was comparable in the AVD (84.4%) and ABVD (85.7%) groups. Three-years OS was also similar, 97.6% and 97.2%, respectively. These results offer a PET-adapted approach reducing bleomycin exposure, which translates into a lower incidence of pulmonary toxicity without compromising efficacy [18].

Immunotherapy as frontline therapy

The risk-adapted and response-adapted approaches discussed above rely mainly on intensification or de-escalation chemotherapy. More recent approaches combine novel immunotherapies such as Brentuximab vedotin (BV) and anti-PD-1 monoclonal antibodies (mAb) to reduce the risk of relapse and chemotherapy-associated toxicity. BV, an antibody–drug conjugate that selectively targets tumour cells expressing the CD30 antigen, was initially added to ABVD and subsequently replaced bleomycin to avoid pulmonary toxicity [19]. The ECHELON-1 randomized phase III trial compared six cycles of ABVD to six cycles of BV plus AVD as frontline treatment for 1334 patients with advanced cHL. The 3-year modified PFS was moderately improved with BV-ABVD (83.1% versus 76% with ABVD) [20]. This benefit of BV-ABVD was confirmed at 5 years with a PFS of 82.2% compared to 75.3% with ABVD (HR = 0.681, p = 0.002) [21]. However, no significant difference was observed in terms of OS. Peripheral neuropathy, neutropenia and infections were more frequent in the BV-ABVD arm reduced with the use of prophylactic granulocyte colony-stimulating factor while pulmonary complications were lower in the BV-ABVD. Hence, BV-ABVD is a safe new frontline option for patients with advanced-stage cHL allowing durable efficacy without the need for treatment intensification or bleomycin exposure.

The use of sequential pembrolizumab (PEM) and AVD for untreated early unfavourable or advanced-stage cHL was evaluated in a phase II study. Thirty patients were treated sequentially with three cycles of PEM followed by four to six cycles of AVD chemotherapy based on the initial stage with no consolidative radiotherapy. Following PEM monotherapy, 11 (37%) patients achieved a complete metabolic response (CMR), and 7 of 28 (25%) patients had >90% reduction of the MTV. Following two cycles of AVD, 100% of the patients had a sustained CMR. After a median follow-up of 22.5 months, there have been no changes in therapy, progression, or death and treatment was well tolerated. PFS and OS rates were 100%. Overall, sequential PEM and AVD were safe and highly active in this population [22].

Nivolumab (nivo) is highly effective in R/R cHL but has not been adequately studied in frontline therapy. A multicentre, phase II, randomized NIVAHIL trial evaluated the efficacy of two experimental Nivolumab-based first-line treatment strategies [23]. Early stage unfavourable cHL patients aged 18–60 years were included. Randomization was to either Arm A: concomitant systemic treatment with four cycles of Nivo and AVD (Nivo-AVD), or Arm B: sequential treatment with four doses of Nivo followed by two cycles of Nivo-AVD and two cycles of AVD at standard doses. Both groups then received 30-Gy involved-site radiotherapy (ISR). Serious adverse events (AE) occurred in 38% and 28% of Arm A and Arm B, respectively. Treatment-related morbidity defined as grade ≥3 organ toxicity, or anaemia, thrombocytopenia, or infection of grade 4 was documented in 16% and 22% of patients, respectively. At the first interim restaging after two cycles of Nivo-AVD or four cycles of Nivo, the overall response rate (ORR) was 100% and 96%, and the complete response (CR) rate was 85% and 53%, respectively. At the end of systemic treatment, the ORR was 100% and 96%, and the CR rate was 81% and 86%, respectively. The 1-year PFS and OS were 98% and 100% and the 2-year PFS and OS were 98% and 100%, respectively [23, 24]. Overall, concomitant and sequential therapy with Nivo-AVD is feasible with acceptable toxicity, high early CR rate and promising 2-year PFS.

In summary, the addition of immunotherapies to established chemotherapy results in improved outcomes. In terms of toxicity, these new advances make it possible to avoid the toxicity of bleomycin and even radiotherapy in some cases. However, these new agents can induce immune-related AEs or peripheral neuropathy. To assess the benefit and optimal use of immunotherapies as a frontline treatment for patients with cHL, further investigations in randomized trials are warranted. The results of the ongoing phase III trial (NCT03907488) comparing Nivo-AVD to BV-AVD are of particular interest.

Novel reduced-toxicity approaches for elderly patients

Patients aged >60 years represent 20–30% of all cHL. The disease is usually aggressive and characterized by unfavourable prognostic factors and poor tolerance to chemotherapy resulting in significantly reduced survival compared to younger patients. In R/R cHL, prospective and retrospective studies have shown that bendamustine monotherapy provides interesting efficacy and an acceptable toxicity profile [25–27]. A combination regimen of prednisone, vinblastine, doxorubicin and bendamustine (P/AVB) for first-line therapy of older patients showing high CMR, 2-year OS; 2-year PFS were 77%, 84% and 61%, respectively, with an acceptable toxicity profile, a particularly favourable outcome but long-term follow-up for survival is needed (Table 1) [28].

As an attempt to decrease chemotherapy exposure in elderly cHL patients, BV and anti-PD-1 mAb are now combined with chemotherapy or administered as a single agent. A promising approach is the sequential administration of two cycles of BV alone followed by six cycles of AVD and four consolidative doses of BV in responding patients. Forty-eight patients with a median
### Table 1. Summary of phase I, II and III trials and retrospective studies in Hodgkin Lymphoma.

| Trial                                      | Design         | Study population | Study arms                                                                 | Outcome                                                                                     |
|--------------------------------------------|----------------|------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| **Frontline**                              |                |                  |                                                                            |                                                                                            |
| NU16H08 [74]                               | Phase II       | > 18 years       | PEM followed by AVD                                                          | After PEM: 37%, CMR 25%, >90% decrease MTV on PET-CT. After AVD: All CMR                   |
|                                            |                | N = 30           |                                                                            |                                                                                            |
| NIVAHL [23]                                | Phase II       | 18–60 years      | Arm A: Nivo + AVD x4<br>A臂 B: Nivo x4 then Nivo + AVD x2 then AVD x2       | ORR: Arm A: 100%, B: 96%<br>CR: Arm A: 81%, B: 86%<br>1-year PFS: 98%<br>1-year OS: 100%          |
|                                            |                | N = 110          |                                                                            |                                                                                            |
| Trial of the LYSA group [28]               | Phase II       | > 60 years       | PVAB x6                                                                     | CMR: 77%<br>2-year OS: 84%<br>2-year PFS: 61%                                               |
|                                            |                | N = 89           |                                                                            |                                                                                            |
| HD14 [12]                                  | Randomized parallel arm trial | < 60 years Early stage, unfavourable N = 1112 | BEACOPP x2 then ABVD x2 Or ABVD x4 | 10-years PFS: 91.2 vs 85.6%, p < 0.0001<br>10-years OS: 94% vs 94.1                           |
|                                            |                |                  |                                                                            |                                                                                            |
| NCT01716806 [41]                           | Phase II       | > 60 years       | BV + Nivo ≤ 16 cycles                                                       | ORR: 100%, CR rate: 72%, PR rate: 28%                                                     |
|                                            |                | N = 19           |                                                                            |                                                                                            |
| **Salvage therapy**                        |                |                  |                                                                            |                                                                                            |
| Stamatoullas et al. [35]                   | Phase I/II     | N = 42           | BV-ICE x2 then if CMR BV-ICE x1 then BV x1 then ASCT                        | CMR: 69.2%, PR: 25.6%<br>1-year PFS: 69%                                                   |
|                                            |                |                  |                                                                            |                                                                                            |
| Herrera et al. [36]                        | Phase II       | N = 39           | Nivo x6<br>If CR -> ASCT<br>If no CR -> Nivo-ICE x2                       | ORR: 85%, CR: 67%<br>2-year PFS: 78% (if ASCT, 91%)<br>2-year OS: 93%                          |
|                                            |                |                  |                                                                            |                                                                                            |
| Moskowitz et al. [37]                      | Phase II       | N = 39           | PEM-GVHD x2-4 then ASCT                                                      | ORR: 100%, CR rate: 95%, PR rate: 5%<br>No relapse or death (median follow-up 11.2 months) |
|                                            |                |                  |                                                                            |                                                                                            |
| Herrera et al. [39, 40]                    | Phase I/II     | ≥18 years        | BV + Nivo x4<br> +/- - ASCT                                                  | ORR: 69%/16%<br>Cohort A: 65%/29%<br>Cohort B: 68%/13%<br>Cohort C: 73%/12%<br>Median PFS: Overall: 14.7 m<br>Cohort A: 18.3 m<br>Cohort B: 14.7 m<br>Cohort C: 11.9 m |
|                                            |                | N = 61           |                                                                            |                                                                                            |
| LaCasce [38]                               | Phase I/II     | N = 53           | BvB ≤ 6 cycles then ASCT or BV x14                                          | CR: 95% (if ASCT, 94%)<br>2-year PFS: 69.8% (if ASCT, 63%)                               |
|                                            |                |                  |                                                                            |                                                                                            |
| Checkmate 205 [75]                         | Phase II       | N = 276          | Nivo after ASCT<br>Cohort A: BV naive N = 60<br>Cohort B: Failure of BV post-ASCT N = 60<br>Cohort C: After BV before and/or after ASCT failure | ORR/CR: Overall: 69%/16%<br>Cohort A: 65%/29%<br>Cohort B: 68%/13%<br>Cohort C: 73%/12%<br>Median PFS: Overall: 14.7 m<br>Cohort A: 18.3 m<br>Cohort B: 14.7 m<br>Cohort C: 11.9 m |
|                                            |                |                  |                                                                            |                                                                                            |
| **Primary refractory disease**             |                |                  |                                                                            |                                                                                            |
| KEYNOTE-024 [58]                           | Phase III      | ≥18 years        | PEM vs BV                                                                   | mPFS: 13.2 vs 8.3 m                                                                        |
|                                            |                | N = 304          |                                                                            |                                                                                            |
| **CPI before allo-HCT**                    |                |                  |                                                                            |                                                                                            |
| Merryman et al. [62, 76]                    | Retrospective  |                  | Pts treated with anti-PD1 mAb before transplant N = 150                      | TT: Nivo N = 118, PEM N = 31, avelumab N = 1<br>Transplant: Haplo (47%), MSD (19%), MUD (26%), MMUD (5%), CB (1%), unknown (1%)<br>Transplant: 2-year PFS: 65%<br>2-year OS: 79%<br>2-year NRM: 14%<br>6-m CI of grade 2-4 aGVHD: 39%<br>6-m CI of grade 3-4 aGVHD: 16%<br>2-year CI of cGVHD: 45% |
|                                            |                |                  |                                                                            |                                                                                            |
| Manson et al. [62]                         | Retrospective  |                  | Pts treated with Nivo with a cohort of allo-SCT N = 17                      | TT: Nivo Transplant<br>Transplant: 1-year PFS: 76%<br>1-year OS: 82%<br>1-year TRM: 17.6%<br>Grade 2-4 aGVHD: 82%<br>cGVHD: 29% |
|                                            |                |                  |                                                                            |                                                                                            |
| El Cheikh et al. [77]                      | Retrospective  |                  | Nivo followed by allo-SCT N = 9                                             | TT: Nivo N = 9<br>Transplant: Haplo (67%)<br>MSD (33%)<br>Grade 2-4 aGVHD: 100%<br>cGVHD: 33% |
|                                            |                |                  |                                                                            |                                                                                            |
| **CPI for relapse after allo-HCT**         |                |                  |                                                                            |                                                                                            |
| Herbaux et al. [69]                        | Retrospective  |                  | Relapse after allo-SCT N = 20                                               | Nivo<br>ORR: 95%, CR: 42%, PR: 52%<br>1-year PFS: 58%<br>1-year OS: 79%<br>GvHD: 30% of pts |
|                                            |                |                  |                                                                            |                                                                                            |
Post-ASCT strategies have been developed to prevent or delay progression, particularly in high-risk patients. The AETHERA trial demonstrated that 1 year of BV maintenance after ASCT for up to 16 cycles is feasible and effective in patients >60 years [41].

**What salvage therapy could be chemotherapy-free?**

In a phase II/II study, patients with R/R cHL received up to four cycles of BV-Nivo as first-salvage therapy followed by ASCT. The ORR among 61 treated patients was 85%, with a CR rate of 67%. Higher responses were seen with higher CD30 + expression. Prior to ASCT, AEs occurred in 98% of patients, mostly grades 1 and 2. A total of 67 (74%) patients underwent ASCT. At a median of 22.6 months, 2-year PFS and OS were 78% and 93% for all patients, respectively. The 2-year PFS was 91% for those who underwent ASCT. The BV-Nivo combination showed tolerability, high CR rates and durable remissions among patients with R/R cHL, potentially providing those patients with an attractive alternative chemotherapy-free regimen [39, 40]. This combination was also shown to be both feasible and efficient in patients >60 years [41].

**Maintenance strategies after ASCT in high-risk patients**

Up to 50% of patients relapse after ASCT, hence, maintenance strategies were developed to prevent or delay progression, more particularly in high-risk patients. The AETHERA trial demonstrated for the first time the benefit of BV maintenance after ASCT for up to 16 cycles. The study included 329 patients with primary R/R cHL.
within 1 year of initial therapy or extranodal relapse. The 5-year PFS was 59% with BV versus 41% with placebo (HR 0.521, 95% CI 0.379–0.717) [42]. Although peripheral neuropathy occurred in 67% of the patients [43], this AE improved and/or resolved in 90% of patients and did not meaningfully impact QoL [44]. No benefit in terms of OS however, has been reported, most likely due to the crossover effect of patients relapsing in the placebo arm and receiving BV subsequently. A shorter duration of BV maintenance (four cycles) after ASCT was tested by Kort et al. with 2-year PFS and OS of 72% and 100%, respectively [45].

Anti-PD1 mAb might also become a new standard for maintenance after ASCT, allowing a schedule twice as short than in the AETHERA trial. A phase II study evaluated PEM administered after ASCT for up to eight cycles in 30 patients with R/R cHL. Toxicities were manageable and the 18-month PFS was 82% [46]. More recently, data of eight cycles of BV-Nivo combination for post-ASCT maintenance were presented at the 2020 ASH meeting. The 18-month PFS was 92% with an acceptable safety profile [47]. Nevertheless, randomized comparative trials are warranted to confirm the benefit of post-ASCT maintenance using anti-PD1 mAb.

ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION

Although most of the cHL patients can be cured with first- and second-line therapy, some patients may still relapse or progress after intensive chemotherapy and ASCT, and thus, carry a poor prognosis. Most salvage therapeutic options now incorporate the use of BV or anti-PD1 mAb, either as monotherapy or in combination. Other promising approaches use the triplet combination of BV-Nivo with iltiimubab (a check point inhibitor [CPI]) [48], new antibody–drug conjugates such as camidanumbum tesirine [49, 50], AFM13 (an anti-CD30/CD16A-bispecific antibody) [51], or chimeric antigen receptor (CAR) T-cell therapy [52]. However, these new advances in the management of cHL have only been evaluated in small series with phase I/II, single arm studies and warrant further investigation.

Fit patients who relapse after ASCT may benefit from allogeneic hematopoietic cell transplantation (allo-HCT) with non-myeloablative conditioning (NMAC) or reduced-intensity conditioning (RIC). A retrospective multicentre study of 98 consecutive patients with cHL who underwent RIC or NMAC allo-HCT at 24 French and Belgian centers compared outcome with haploidentical (Haplo, n = 34), mismatched unrelated (MMUD, n = 27) or cord blood (CB, n = 37) donors. All patients in the Haplo group received T-cell replete NMAC transplant with post-transplant cyclophosphamide (PT-Cy). After a median follow-up of 31 months, the OS and PFS in the Haplo group were 75% and 66%, respectively, with no difference with the two other donor groups. The CI of grade 3–4 acute graft-versus-host disease (aGvHD) and chronic (c) GvHD were 3% and 15%, respectively, both being significantly lower in the Haplo cohort compared to the other groups. The non-relapse mortality (NRM) for the whole cohort was 12%. A significantly higher probability of GvHD-free, relapse-free survival (GRFS) was observed in patients who received Haplo (52% versus 22% and 31% in the CB and MMUD groups at 3 years, respectively, p = 0.02). The authors concluded that in the absence of an HLA-identical donor, a T-cell replete, NMAC Haplo with PT-Cy was associated with better outcomes compared to other alternative donors for patients with R/R cHL [53].

The question of the best donor type between Haplo (in the era of PT-Cy) and HLA-matched related donor (MRD) for patients with cHL undergoing allo-HCT is still being debated. A multicentre retrospective study analyzed the outcome of 151 cHL patients undergoing NMAC/RIC allo-HCT from Haplo (n = 61) or MRD (n = 90). In the Haplo group, OS, relapse incidence, and NRM were 81%, 21% and 9%, respectively, with no significant difference compared to the MRD group. Donor type had a significant impact on GRFS at 2 years (58% versus 42% in the Haplo and MRD groups, respectively, p = 0.03). In the multivariate analysis, MRD donors were independently associated with lower GRFS compared to Haplo donors (HR = 2.95, p < 0.001). Not achieving CR at time of allo-HCT was also associated with lower GRFS (HR = 1.74, p = 0.01). In summary, the Haplo PT-Cy platform significantly improved GRFS in patients receiving allo-HCT compared to MRD [54]. The favourable results with Haplo and PT-Cy were also confirmed in a large European Society for Blood and Marrow Transplantation (EBMT) study comprising 240 cHL patients. The 2-year OS and PFS were 72% and 57%, respectively [55].

IMMUNOTHERAPIES AS A BRIDGE TO ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION?

In a large EBMT study, BV was assessed as a bridge to allo-HCT in patients with R/R cHL compared to a group of no BV therapy prior to allo-HCT [56]. In multivariate analysis, pre-transplant BV had no significant effect on non-relapse mortality (NRM), relapse incidence, PFS, or OS, but significantly reduced the incidence of cGvHD. A French retrospective study looked at the use of BV monotherapy in patients with R/R cHL. Among the 145 patients that responded to BV, 54 patients received consolidation allo-HCT with a median PFS of 18.8 versus 8.7 months for the 91 patients without transplant (p < 0.0001). Those results from real-life settings confirm the importance of considering BV as a bridge to transplant and support the previously reported BV efficacy and manageable toxicity. Because of the short-term responses in most patients, the authors recommended that allo-HCT consolidation for responders should be considered as quickly as possible [57]. Results of a study comparing BV to PEM showed a significant improvement in median PFS among 304 R/R cHL patients receiving PEm versus BV (13.2 versus 8.3 months; HR = 0.65; 95%CI, 0.48–0.88, p = 0.0027). One-year PFS rates were 53.9% and 35.6%, respectively. The authors stated that PEM monotherapy should be standard of care for this patient population [58] and believe that BV will be used early in the disease course, not as monotherapy but in combination. However, several reports suggested that anti-PD1 mAb might be associated with increased toxicity, notably severe aGvHD [59–61]. These results prompted a warning and raised challenging questions about the role, timing, optimal modalities, long-term efficacy and the need for consolidation allo-HCT after anti-PD1 mAb. A retrospective study analyzed 78 patients with R/R cHL treated with Nivo in the French Early Access Program and compared their outcomes after subsequent allo-HCT. Among responding patients, none of the patients undergoing allo-HCT relapsed, whereas 62.2% of patients who were not consolidated with allo-HCT relapsed. Most patients treated with anti-PD1 mAb monotherapy eventually progressed, notably those who did not achieve CR. Patients undergoing consolidation with allo-HCT after anti-PD1 therapy experienced prolonged PFS compared with non-transplanted patients, but this difference did not translate into an OS benefit. This information should be considered when evaluating the risk/benefit ratio of allo-HCT after anti-PD1 mAb [62]. Pre-transplant exposure to anti-PD1 mAb may indeed improve PFS in patients who receive Haplo with PT-Cy. In a study of 59 cHL patients, outcomes based on pre-transplant exposure to anti-PD1 mAb were compared. The 2-year OS and PFS were 77% versus 71% (p = 0.599) and 78% versus 53% (p = 0.066), respectively. The 2-year relapse/progression rate was 22% in the no-CPI cohort and 4% in the CPI cohort (p = 0.098). PD1-1 blockade as a bridge to Haplo with PT-Cy did not increase toxicities or NRM, and CPI before Haplo seemed to improve PFS [63].

An important retrospective cohort study of 209 cHL patients undergoing allo-HCT after anti-PD1 mAb was recently published. With a median follow-up of 24 months, the 2-year cumulative incidences of NRM and relapse were 14% and 18%, respectively;
the 2-year GRFS, PFS and OS were 47%, 69% and 82%, respectively. The 180-day cumulative incidence of grade 3–4 aGvHD was 15% and the 2-year cumulative incidence of cGvHD was 34%. In the multivariable analysis, longer interval from anti-PD-1 mAbs to allo-HCT (> 80 days) was associated with less frequent grade 3–4 aGvHD (HR = 0.4, p = 0.01), while additional treatment between anti-PD-1 mab and allo-HCT was associated with a higher risk of relapse (HR = 2.9, p = 0.003). Notably, PT-Cy was associated with significant improvements in PFS and GRFS. The authors conclude that allo-HCT after anti-PD-1 mAb is associated with favourable outcomes. Their data strongly suggest that anti-PD-1 mAb impacts the post-allo-HCT course both in terms of toxicity and efficacy. Most notably, PT-Cy may represent the optimal transplant strategy for this patient population [64].

Why does PT-Cy prophylaxis improve outcomes?

A recent study of 18 patients showed that the anti-PD-1 mAb Nivo can persist in plasma after transplantation for up to 56 days. Nivo binds and blocks anti-PD-1 on allogeneic T-cells and generates an increased T-cell activation. Nivo exposed patients had a higher incidence of severe GvHD, and a higher expression of effector T-cells compared with anti-PD-1-naive patients. However, patients receiving PT-Cy showed a similar risk of aGvHD and T-cell profile irrespective of the previous Nivo exposure. This T-cell activation status can be mitigated with the use of PT-Cy, thus reducing the risk of aGvHD [65].

With respect to the use of anti-PD-1 mAbs before allo-HCT, conclusions are as follows:

- For patients with R/R cHL, the use of anti-PD-1 mAbs until progression seems to be suboptimal when a curative option can be considered: a consolidative strategy with allo-HCT should be discussed for all responding patients.
- Allo-HCT performed after anti-PD-1 therapy is a feasible strategy associated with an excellent PFS and a low cumulative incidence of relapse.
- Patients undergoing allo-HCT after anti-PD-1 therapy experience prolonged PFS compared with non-transplanted patients.
- PT-Cy is associated with improved outcomes and reduced risk of GvHD: this GvHD prophylaxis should be considered for all cHL patients undergoing allo-HCT after anti-PD1 mAbs, even in the case of MMUD and MRD.

IMMUNOTHERAPIES FOR RELAPSE AFTER ALLOGENEIC HCT

Although long-term disease control after allo-HCT can be achieved, post-transplant relapse is still common. One of the earliest immunotherapeutic modalities used for relapse after allo-HCT is donor lymphocyte infusion (DLI). Peggs et al. reported the outcome after DLI infusion for relapsed cHL after allo-SCT. The ORR was 56% in all patients. Four patients died of severe GvHD [66]. In a retrospective study, DLI was combined to bendamustine for the treatment of nine patients with relapsed cHL after allo-HCT. The probability of being alive and in CR was highest in the group that did not receive BV (p = 0.003). The combination of BV with donor lymphocyte infusion was associated with the highest probability of being alive in CR at the time of last follow-up [68].

Our choice of treatment for relapse after allo-HCT is to first try BV, either alone or in combination with bendamustine, plus donor lymphocyte infusion (DLI), depending on patient and disease history. In the case of failure, we will use anti-PD-1 mAbs as it allows good disease control and, unfortunately, there are few other options for survival. One should definitely be cautious when using anti-PD1 mAb after BV and DLI because of the increased risk of acute GvHD. Badar et al. recently assessed the use of oral ibrutinib, a small molecule drug (and another alternative Bruton’s tyrosine kinase (BTK) inhibitor), in seven patients relapsing after allo-HCT, as an alternative for patients with a prior history of GvHD. Four (57%) patients achieved response (CR n = 3, PR, n = 1) and, overall, ibrutinib was well-tolerated [71]. These results need to be confirmed in larger trials.

QOL AND LONG-TERM SIDE EFFECTS

Aside from striving to improve response rates, consideration of QoL is equally important. A Norwegian study compared health-related quality of life (HRQoL), assessed by the Short Form 36 (SF-36), in 456 cHL survivors with 2214 normals from the general Norwegian population. They examined the effect of disease characteristics and treatment on differences in HRQoL and demonstrated reduced HRQoL 3–23 years (adjusted for age, gender and educational status) after curative treatment primarily in physical health including physical functioning, role limitations due to physical problems and general health perceptions, compared to the general Norwegian population. Statistically significant differences were found in general health, physical functioning, role limitations (physical), social functioning and in
vitality. Time since diagnosis, types of primary treatment, and relapse, were not associated with statistically significant differences in HRQoL [72].

In the H8 randomized trial, HRQoL data from 935 patients after treatment for early stage cHL showed strain and limitations in all subdomains apart from cognitive functioning, and also reduced motivation. Differences in HRQoL improvement with time were linked to age and sex, but not the type of treatment. Also, patients can be included in clinical trials using novel agents or cellular therapy. Allo-SCT remains the standard of care for fit and responding patients. PT-Cy should be considered as GvDH prophylaxis for all patients undergoing allo-SCT, even in the non-haploidentical settings. HL: Hodgkin Lymphoma; ABVD: Adriamycin, Bleomycin, Vincristine, Dacarbazine; eBEACOPP: bleomycin, etoposide, doxorubicin (aka adriamycin), cyclophosphamide, vincristine (aka oncovin), procarbazine, prednisolone; PET: positron emission tomography; BV: brentuximab vedotin; AVD: Adriamycin, Vincristine, Dacarbazine; GVD: gemcitabine, vinorelbine, liposomal doxorubicin; CR: complete response; ICE: ifosfamide, mesna, carboplatin, etoposide; ASCT: autologous stem cell transplantation; PD1: programmed cell death 1; mAbs: monoclonal antibodies; CPI: checkpoint inhibitors; Allo-SCT: allogeneic stem cell transplantation; PT-Cy: post-transplant cyclophosphamide; GvHD: graft-versus-host disease.

Fig. 1 Suggested treatment algorithm for advanced-stage classical Hodgkin Lymphoma. In the frontline setting, patients are treated according to age. In patients aged <60 years, the treatment options can be either immunotherapy (BV) combined with AVD or risk-adapted PET-guided approaches using ABVD and/or eBEACOPP. In patients aged >60 years, the intensity of therapies should be adapted to comorbidities. In the relapsed setting, chemoimmunotherapeutic or chemotherapy-free approaches can be used. ASCT is recommended for fit patients followed by BV maintenance for high-risk patients (a shorter duration of BV or the use of anti-PD1 mAbs alone or in combination with BV may be considered). Beyond third-line therapy, immunotherapy can be used as single agent or in combination. Also, patients can be included in clinical trials using novel agents or cellular therapy. Allo-SCT remains the standard of care for fit and responding patients. PT-Cy should be considered as GvDH prophylaxis for all patients undergoing allo-SCT, even in the non-haploidentical settings. HL: Hodgkin Lymphoma; ABVD: Adriamycin, Bleomycin, Vincristine, Dacarbazine; eBEACOPP: bleomycin, etoposide, doxorubicin (aka adriamycin), cyclophosphamide, vincristine (aka oncovin), procarbazine, prednisolone; PET: positron emission tomography; BV: brentuximab vedotin; AVD: Adriamycin, Vincristine, Dacarbazine; GVD: gemcitabine, vinorelbine, liposomal doxorubicin; CR: complete response; ICE: ifosfamide, mesna, carboplatin, etoposide; ASCT: autologous stem cell transplantation; PD1: programmed cell death 1; mAbs: monoclonal antibodies; CPI: checkpoint inhibitors; Allo-SCT: allogeneic stem cell transplantation; PT-Cy: post-transplant cyclophosphamide; GvHD: graft-versus-host disease.

The effects of treatment on QoL can really jeopardise a patient’s return to normal life, with familial, social, and professional consequences. There are many guidelines to help with the treatment of cHL resulting from numerous randomized controlled trials, but the patient cure does not just depend on prescribing the right treatment. Emphasis on HRQoL following therapy may inform treatment decisions and long-term survivorship goals. To improve HRQoL, clinicians need to learn more about the impact of treatments on HRQoL. Future research should include prospective, longitudinal randomized trials across both treatments and time. They also need to gain further insight into the course of recovery after cure, considering all aspects of
life, not only physical but also functional, social and psychological domains. HRQoL will also be improved by the development of new, more effective but less toxic therapies.

**SUMMARY AND CONCLUDING REMARKS**

The management of cHL has a huge effect on patients’ QoL not only due to the treatment but also due to the strain and limitations experienced in most aspects of life. In frontline therapy, further individualized intensity with PET-guided therapy may reduce treatment-related morbidity and help prevent relapse by using escalating or de-escalating approaches with ABVD and BEACOPP regimens. Another valid frontline option is the combination of BV with AVD, especially in patients who have a contraindication to bleomycin (Fig. 1).

Future perspectives include sequential strategies and the use of anti-PD-1 mAb in combination with AVD. In elderly patients (>60 years), the use of PVAB or the sequential combination of BV-AVD are attractive approaches. Certainly, there is a need for randomized controlled trials to compare the new combination therapies. Regarding second-line treatment, the latest advances show that immunotherapies can safely be combined with chemotherapy followed by consolidation with ASCT in responders. The following treatments showed promising results as first-salvage therapy:

- **BV-ICE** (ORR 95%, PFS 69%)
- **Nivo-ICE** (ORR 90%, PFS 79%)
- **PEM-GVD** (ORR 100%, 1-year PFS 100%)
- **BV-Nivo** (ORR 85%, PFS 91% after ASCT)
- **BV-Bendamustine** (ORR 92.5%, PFS 75%)

For patients with a higher risk of relapse, post-ASCT BV maintenance should be given, regardless of remission status or prior BV exposure. Allo-HCT performed after anti-PD-1 mAb is a feasible strategy associated with an excellent PFS and a low incidence of relapse. PT-Cy should be considered for all cHL patients treated with anti-PD1 mAb to reduce the risk of GvHD.

Finally, CAR T-cell therapy, not discussed here given the few clinical data to date, but hopefully [52], will also be available and useful for many patients.

**REFERENCES**

1. Connors JM. Hodgkin’s lymphoma: the hazards of success. J Clin Oncol. 2003;21:3388–90.
2. Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J, et al. Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann Oncol. 2013;24:3070–6.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–14.
4. Armitage JO. Early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:653–62.
5. Jerusalem G, Beguin Y, Fassotte MF, Najar F, Paulus P, Pigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86:266–73.
6. Gailaini A, Hutchings M, Riggaci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.
7. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.
8. Kanoun S, Rossi C, Bernilo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, et al. Baseline metabolic tumor volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43.
9. Corazzelli G, Angrilli D, D’Arco A, Ferrara F, Musto P, Guarini A, et al. Efficiency and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–15.
10. Moskowitz AJ, Hamlin PA, Jr, Perales MA, Gerecitano J, Howitz SM, Matsaraj M, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456–60.
11. Ghesquiere H, Stamatoullas A, Casanosovas O, Morschhauser F, Gyan E, Gaborre J, et al. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leuk Lymphoma. 2013;54:2399–404.
12. Cheson BD, Bartlett NL, LaPlant B, Lee JH, Advani RJ, Christian B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCQUI: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020;7:e608–e15.

**SPRINGER NATURE**

BLOOD CANCER JOURNAL (2021) 11:126
30. Yasenchak CA, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia RV, et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. Blood. 2020;136:18–9.

31. Friedberg JW, Forero-Torres A, Bordoni RE, Cline V, Patel Donnelly D, Flynn PJ, et al. Brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017;130:2829–37.

32. Linch DC, Winfield S, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNII randomised trial. Lancet. 1993;341:1051–4.

33. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

34. Younes A, Smith SE, Ansell SM, Ansell S, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–9.

35. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Hancock H, Davey T, et al. Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. Blood. 2020;136:17–8.

36. Herreraerrera AF, Chen RW, Palmer J, Tsai NC, Mei M, Popplewell LL, et al. PET-CT monitoring of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101:466–73.

37. Kort J, Chidiac A, El Sayed R, Massoud R, Nehme R, Bazarbachi A, et al. Safety and efﬁcacy of allogeneic hematopoietic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2017;52:869–96.

38. Gauthier J, Poire X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, et al. Better outcome with haploidential over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2018;53:400–9.

39. Gauthier J, Poire X, Gac AC, Leclerc M, Guillaume T, Chalandon Y, et al. Better outcome with haploidential over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2018;53:400–9.

40. Barazbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidential transplantation for Hodgkin lymphoma—a LWP-EBMT study. Br J Haematol. 2020;188:745–56.

41. Barazbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018;188:186–96.
70. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221–8.

71. Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M. Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. Br J Haematol. 2020;190:e98–e101.

72. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. Ann Oncol. 1999;10:71–7.

73. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, et al. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10:1160–70.

74. Allen PB, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. Blood. 2020;137:1318–26.

75. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428–39.

76. Merryman R, Castagna L, Corradini P, Ho VT, Bond DA, Jaglowski S, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade for classical Hodgkin lymphoma: analysis of a large international cohort. Blood. 2019;134:775–775.

77. El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Khafraf-Dabaja MA, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:1074–7.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to M.M.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021